Liquidia Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Roger A. Jeffs
- Full Time Employees
- 216
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 419 Davis Drive Morrisville NC United States of America 27560
- IPO Date
- Jul 26, 2018
- CIK
- 0001819576
- Website
- liquidia.com
- Similar Companies
- Business
- Liquidia Corporation Liquidia Corporation (LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes products addressing unmet needs in rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD); its core offerings center on YUTREPIA, an inhaled dry powder formulation of treprostinil, alongside investigational therapies such as L606, a liposomal sustained-release formulation of treprostinil licensed from Pharmosa Biopharm Inc., and references to related products like Yutopia for inhalation and generic treprostinil options, all leveraging proprietary PRINT particle engineering technology for precise drug particle production. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates primarily in the United States through wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, targeting patients with rare respiratory conditions via innovative drug delivery systems that enhance convenience and efficacy. Recent developments include a $67.5 million common stock financing in September 2024 comprising a public offering and private placement with Caligan Partners LP, plus a $32.5 million advance under a fifth amendment to its Revenue Interest Financing Agreement with HealthCare Royalty, bringing total non-dilutive funding to $100 million and extending the agreement term to 2031 while supporting YUTREPIA commercialization, pediatric trials, and L606 advancement ahead of expected 2025 launch post-FDA tentative approval for PAH and PH-ILD; third quarter 2025 results highlighted launch momentum for YUTREPIA and improved profitability.
Company News
FDA Grants Fast Track Designation to YUTREPIA® for the Treatment of Raynaud's Phenomenon Associated with Systemic Sclerosis
Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress
Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference
Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
Is the Options Market Predicting a Spike in Liquidia Stock?
Liquidia Corp (LQDA) Stock Down 3.1% -- Now Undervalued? GF Score: 70/100
Liquidia: A Linear Launch Priced For Exponential Growth
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?
Will LQDA's Differentiated PAH Approach Drive Growth?
Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors
Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion?
Handelsbanken Fonder AB Invests $1.99 Million in Liquidia Corporation $LQDA
LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now?
Why Liquidia Stock Was Diving This Week
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path
Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow
Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript
Liquidia Q2 Earnings Call Highlights
Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates